The challenge of modulating β-cell autoimmunity in type 1 diabetes

The Lancet Diabetes and Endocrinology

Volumn 7, Issue 1, 2019, Pages 52-64

  Atkinson, Mark A ^a   Roep, Bart O ^b,c   Posgai, Amanda ^a   Wheeler, Daniel C S ^d   Peakman, Mark ^d,e  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALBIGLUTIDE; ALDESLEUKIN; ALEFACEPT; ALEMTUZUMAB; BCG VACCINE; BIOLOGICAL MARKER; C PEPTIDE; ERGOCALCIFEROL; GOLIMUMAB; HYDROXYCHLOROQUINE; IMATINIB; INSULIN; INTERLEUKIN 2; LADARIXIN; LIRAGLUTIDE; MYCOPHENOLATE MOFETIL; OTELIXIZUMAB; PROBIOTIC AGENT; RAPAMYCIN; RITUXIMAB; SAXAGLIPTIN; SILTUXIMAB; SUBSTANCE P; TEPLIZUMAB; THYMOCYTE ANTIBODY; TOCILIZUMAB; UNINDEXED DRUG; USTEKINUMAB; VILDAGLIPTIN; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL VOLUME; CLINICAL STUDY; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; METABOLISM; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; CELL TRANSPLANTATION; IMMUNOLOGY; PROCEDURES; REGULATORY T LYMPHOCYTE; TRANSPLANTATION;

AUTOIMMUNITY; CELL TRANSPLANTATION; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 85058918769     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30112-8     Document Type: Review

References (95)

1. Ziegler, AG, Bonifacio, E, Powers, AC, Todd, JA, Harrison, LC, Atkinson, MA, Type 1 diabetes prevention: a goal dependent on accepting a diagnosis of an asymptomatic disease. Diabetes 65 (2016), 3233–3239.
2. Stiller, CR, Dupre, J, Gent, M, et al. Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease. J Pediatr 111 (1987), 1069–1072.
3. Chase, HP, Butler-Simon, N, Garg, SK, et al. Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus. Pediatrics 85 (1990), 241–245.
4. Cook, JJ, Hudson, I, Harrison, LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 38 (1989), 779–783.
5. Sobel, DO, Henzke, A, Abbassi, V, Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol 47 (2010), 243–250.
6. Roep, BO, Wheeler, DCS, Peakman, M, Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol, 2018 published online Oct 24. http://dx.doi.org/10.1016/S2213-8587(18)30109-8.
7. Herold, KC, Hagopian, W, Auger, JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes. N Engl J Med 346 (2002), 1692–1698.
8. Keymeulen, B, Vandemeulebroucke, E, Ziegler, AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005), 2598–2608.
9. Pescovitz, MD, Greenbaum, CJ, Krause-Steinrauf, H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361 (2009), 2143–2152.
10. Rigby, MR, Harris, KM, Pinckney, A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 125 (2015), 3285–3296.
11. Orban, T, Beam, CA, Xu, P, et al. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 63 (2014), 3449–3457.
12. Gitelman, SE, Gottlieb, PA, Felner, EI, et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia 59 (2016), 1153–1161.
13. Gottlieb, PA, Quinlan, S, Krause-Steinrauf, H, et al. Failure to preserve β-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 33 (2010), 826–832.
14. Long, SA, Rieck, M, Sanda, S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 61 (2012), 2340–2348.
15. Hartemann, A, Bensimon, G, Payan, CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1 (2013), 295–305.
16. Rosenzwajg, M, Churlaud, G, Mallone, R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun 58 (2015), 48–58.
17. Yu, A, Snowhite, I, Vendrame, F, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64 (2015), 2172–2183.
18. Truman, LA, Pekalski, ML, Kareclas, P, et al. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. BMJ Open, 5, 2015, e009799.
19. Todd, JA, Evangelou, M, Cutler, AJ, et al. Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med, 13, 2016, e1002139.
20. Long, SA, Thorpe, J, DeBerg, HA, et al. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol, 1, 2016, eaai7793.
21. Insel, RA, Dunne, JL, Atkinson, MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38 (2015), 1964–1974.
22. AlMutairi, N, Abouzaid, HA, Safety of biologic agents for psoriasis in patients with viral hepatitis. J Dermatolog Treat, 2018 published online Feb 1. DOI:10.1080/09546634.2018.1430301.
23. McKinnon, RA, Cook, M, Liauw, W, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs 32 (2018), 27–52.
24. Saldanha, M, Dandekar, P, Jain, R, A regulatory perspective on testing of biological activity of complex biologics. Trends Biotechnol 36 (2018), 231–234.
25. Lockwood, SJ, Prens, LM, Kimball, AB, Adverse reactions to biologics in psoriasis. Curr Probl Dermatol 53 (2018), 1–14.
26. Coppieters, KT, Dotta, F, Amirian, N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209 (2012), 51–60.
27. Leete, P, Willcox, A, Krogvold, L, et al. Differential insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes 65 (2016), 1362–1369.
28. Willcox, A, Gillespie, KM, Histology of type 1 diabetes pancreas. Methods Mol Biol 1433 (2016), 105–117.
29. Willcox, A, Richardson, SJ, Bone, AJ, Foulis, AK, Morgan, NG, Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia 53 (2010), 2020–2028.
30. Willcox, A, Richardson, SJ, Bone, AJ, Foulis, AK, Morgan, NG, Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155 (2009), 173–181.
31. Atkinson, MA, Leiter, EH, The NOD mouse model of type 1 diabetes: as good as it gets?. Nat Med 5 (1999), 601–614.
32. Roep, BO, Atkinson, M, von Herrath, M, Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 4 (2004), 989–997.
33. Atkinson, MA, Evaluating preclinical efficacy. Sci Transl Med, 3, 2011, 96cm22.
34. Sarikonda, G, Sachithanantham, S, Manenkova, Y, et al. Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS One, 8, 2013, e54712.
35. Gill, RG, Pagni, PP, Kupfer, T, et al. A preclinical consortium approach for assessing the efficacy of combined anti-CD3 plus IL-1 blockade in reversing new-onset autoimmune diabetes in NOD mice. Diabetes 65 (2016), 1310–1316.
36. Chatenoud, L, Thervet, E, Primo, J, Bach, JF, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91 (1994), 123–127.
37. Chatenoud, L, Primo, J, Bach, JF, CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158 (1997), 2947–2954.
38. Alkemade, GM, Hilbrands, R, Vandemeulebroucke, E, et al. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. Diabetes Metab Res Rev 27 (2011), 925–927.
39. McNamee, K, Williams, R, Seed, M, Animal models of rheumatoid arthritis: how informative are they?. Eur J Pharmacol 759 (2015), 278–286.
40. Wallet, MA, Santostefano, KE, Terada, N, Brusko, TM, Isogenic cellular systems model the impact of genetic risk variants in the pathogenesis of type 1 diabetes. Front Endocrinol (Lausanne), 8, 2017, 276.
41. Tan, S, Li, Y, Xia, J, et al. Type 1 diabetes induction in humanized mice. Proc Natl Acad Sci USA 114 (2017), 10954–10959.
42. Mayer-Davis, EJ, Lawrence, JM, Dabelea, D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med 376 (2017), 1419–1429.
43. Thomas, NJ, Jones, SE, Weedon, MN, Shields, BM, Oram, RA, Hattersley, AT, Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 6 (2018), 122–129.
44. Oram, RA, Thomas, NM, Jones, SE, Weedon, MN, Hattersley, AT, Analysis of diabetes incidence against type 1 diabetes genetic risk score in 150,000 shows autoimmune diabetes presents as often between 30–60 years as before 30 years. Diabetes, 65(suppl 1), 2016, A413.
45. Raab, J, Haupt, F, Scholz, M, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open, 6, 2016, e011144.
46. Ehehalt, S, Dietz, K, Willasch, AM, Neu, A, Prediction model for the incidence and prevalence of type 1 diabetes in childhood and adolescence: evidence for a cohort-dependent increase within the next two decades in Germany. Pediatr Diabetes 13 (2012), 15–20.
47. Aronson, R, Gottlieb, PA, Christiansen, JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37 (2014), 2746–2754.
48. Ambery, P, Donner, TW, Biswas, N, Donaldson, J, Parkin, J, Dayan, CM, Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet Med 31 (2014), 399–402.
49. Keymeulen, B, Walter, M, Mathieu, C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53 (2010), 614–623.
50. Daifotis, AG, Koenig, S, Chatenoud, L, Herold, KC, Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 149 (2013), 268–278.
51. National Psoriasis Foundation. Amevive (alefacept) voluntarily discontinued in the US. https://www.psoriasis.org/media/press-releases/amevive-alefacept-voluntarily-discontinued-us, 2011. (Accessed 30 May 2018)
52. Rigby, MR, DiMeglio, LA, Rendell, MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 1 (2013), 284–294.
53. Baxter, AG, Jordan, MA, From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era. Rev Diabet Stud 9 (2012), 201–223.
54. Sosenko, JM, Skyler, JS, Beam, CA, et al. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in Diabetes Prevention Trial–Type 1 participants. Diabetes 62 (2013), 4179–4183.
55. Greenbaum, CJ, Beam, CA, Boulware, D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61 (2012), 2066–2073.
56. Herold, KC, Usmani-Brown, S, Ghazi, T, et al. β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 125 (2015), 1163–1173.
57. Mirmira, RG, Sims, EK, Syed, F, Evans-Molina, C, Biomarkers of β-cell stress and death in type 1 diabetes. Curr Diabetes Rep, 16, 2016, 95.
58. Lehmann-Werman, R, Neiman, D, Zemmour, H, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci USA 113 (2016), E1826–E1834.
59. Ludvigsson, J, Heding, L, Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabetol Lat 19 (1982), 351–358.
60. Arif, S, Gibson, VB, Nguyen, V, et al. β-cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with type 1 diabetes compared with adults. Diabet Med 34 (2017), 419–425.
61. Ludvigsson, J, Krisky, D, Casas, R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366 (2012), 433–442.
62. Woittiez, NJ, Roep, BO, Impact of disease heterogeneity on treatment efficacy of immunotherapy in type 1 diabetes: different shades of gray. Immunotherapy 7 (2015), 163–174.
63. Wherrett, DK, Chiang, JL, Delamater, AM, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care 38 (2015), 1975–1985.
64. Ma, X, Xu, S, TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep Eng 2013 (2013), 177–184.
65. Bottazzo, GF, Lawrence lecture. Death of a beta cell: homicide or suicide?. Diabet Med 3 (1986), 119–130.
66. Atkinson, MA, Bluestone, JA, Eisenbarth, GS, et al. How does type 1 diabetes develop? The notion of homicide or β-cell suicide revisited. Diabetes 60 (2011), 1370–1379.
67. Campbell-Thompson, M, Fu, A, Kaddis, JS, et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes 65 (2016), 719–731.
68. Oram, RA, Jones, AG, Besser, RE, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 57 (2014), 187–191.
69. Wasserfall, C, Nick, HS, Campbell-Thompson, M, et al. Persistence of pancreatic insulin mRNA expression and proinsulin protein in type 1 diabetes pancreata. Cell Metab, 26, 2017, 568 75.e3.
70. Rui, J, Deng, S, Arazi, A, Perdigoto, AL, Liu, Z, Herold, KC, β cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice. Cell Metab 25 (2017), 727–738.
71. Bonifacio, E, Mathieu, C, Nepom, GT, et al. Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Diabetologia 60 (2017), 35–38.
72. Campbell-Thompson, M, Fu, A, Kaddis, JS, et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes 65 (2016), 719–731.
73. Yeo, L, Woodwyk, A, Sood, S, et al. Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes. J Clin Invest 128 (2018), 3460–3474.
74. Roep, BO, Atkinson, MA, van Endert, PM, Gottlieb, PA, Wilson, SB, Sachs, JA, Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the First International Workshop for Standardization of T Cell Assays. J Autoimmun 13 (1999), 267–282.
75. Pathiraja, V, Kuehlich, JP, Campbell, PD, et al. Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes. Diabetes 64 (2015), 172–182.
76. Babon, JA, DeNicola, ME, Blodgett, DM, et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med 22 (2016), 1482–1487.
77. Michels, AW, Landry, LG, McDaniel, KA, et al. Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes. Diabetes 66 (2017), 722–734.
78. Seay, HR, Yusko, E, Rothweiler, SJ, et al. Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes. JCI Insight, 1, 2016, e88242.
79. Gomez-Tourino, I, Kamra, Y, Baptista, R, Lorenc, A, Peakman, M, T cell receptor β-chains display abnormal shortening and repertoire sharing in type 1 diabetes. Nat Commun, 8, 2017, 1792.
80. Lu, H, Caen, O, Vrignon, J, et al. High throughput single cell counting in droplet-based microfluidics. Sci Rep, 7, 2017, 1366.
81. Jacobsen, LM, Posgai, A, Seay, HR, Haller, MJ, Brusko, TM, T cell receptor profiling in type 1 diabetes. Curr Diabetes Rep, 17, 2017, 118.
82. Hilbrands, R, Huurman, VA, Gillard, P, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 58 (2009), 2267–2276.
83. Huurman, VA, Hilbrands, R, Pinkse, GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One, 3, 2008, e2435.
84. Velthuis, JH, Unger, WW, Abreu, JR, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 59 (2010), 1721–1730.
85. Malmegrim, KC, de Azevedo, JT, Arruda, LC, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. Front Immunol, 8, 2017, 167.
86. Beam, CA, MacCallum, C, Herold, KC, Wherrett, DK, Palmer, J, Ludvigsson, J, GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia 60 (2017), 43–49.
87. Beam, CA, Gitelman, SE, Palmer, JP, Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes 63 (2014), 3120–3127.
88. Arif, S, Leete, P, Nguyen, V, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 63 (2014), 3835–3845.
89. Dubé, MC, D'Amours, M, Weisnagel, SJ, Beyond glycaemic control: a crossover, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. Diabetes Obes Metab 20 (2018), 178–184.
90. Underland, LJ, Ilkowitz, JT, Katikaneni, R, Dowd, A, Heptulla, RA, Use of sitagliptin with closed-loop technology to decrease postprandial blood glucose in type 1 diabetes. J Diabetes Sci Technol 11 (2017), 602–610.
91. Neal, B, Perkovic, V, Mahaffey, KW, et al. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19 (2017), 915–925.
92. Marré, ML, James, EA, Piganelli, JD, β cell ER stress and the implications for immunogenicity in type 1 diabetes. Front Cell Dev Biol, 3, 2015, 67.
93. Lee, JTC, Shanina, I, Chu, YN, Horwitz, MS, Johnson, JD, Carbamazepine, a beta-cell protecting drug, reduces type 1 diabetes incidence in NOD mice. Nat Sci Rep, 8, 2018, 4588.
94. Miller, KM, Foster, NC, Beck, RW, et al. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care 38 (2015), 971–978.
95. Long, SA, Thorpe, J, Herold, KC, et al. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol 319 (2017), 3–9.